Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 4 | -$0.31 | -$0.24 | -$0.26 |
| Q2 2026 | 1 | -$0.32 | -$0.12 | -$0.25 |
| Q3 2026 | 2 | -$0.26 | -$0.21 | -$0.24 |
| Q4 2026 | 2 | -$0.21 | -$0.19 | -$0.20 |
| Q1 2027 | 2 | -$0.23 | -$0.22 | -$0.22 |
| Q2 2027 | 1 | -$0.26 | -$0.10 | -$0.21 |
| Q3 2027 | 1 | -$0.23 | -$0.08 | -$0.18 |
| Q4 2027 | 1 | -$0.21 | -$0.08 | -$0.17 |
| Q1 2028 | 1 | -$0.18 | -$0.07 | -$0.14 |
| Q2 2028 | 1 | -$0.13 | -$0.05 | -$0.10 |
| Q3 2028 | 1 | -$0.11 | -$0.04 | -$0.09 |
| Q4 2028 | 1 | -$0.09 | -$0.03 | -$0.07 |
Insight Molecular Diagnostics Inc. last posted its earnings results on Monday, November 16th, 2026. The company reported $-0.1 earnings per share for the quarter, topping analysts' consensus estimates of $-0.236 by $0.136. The company had revenue of 559.00 K for the quarter and had revenue of 4.06 M for the year. Insight Molecular Diagnostics Inc. has generated $-2 earnings per share over the last year ($-1.65 diluted earnings per share) and currently has a price-to-earnings ratio of -1.54. Insight Molecular Diagnostics Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/16/2026 | Q3 2026 | -$0.24 | -$0.10 | 0.14 | $244.28 K | $559.00 K |
| 08/10/2026 | Q2 2026 | -$0.25 | -$0.31 | -0.06 | $352.50 K | $239.00 K |
| 05/13/2026 | Q1 2026 | -$0.26 | -$0.12 | 0.14 | $229.23 K | $32.00 K |
| 03/26/2026 | Q4 2025 | -$0.24 | -$0.75 | -0.51 | $285.00 K | $1.14 M |
| 11/10/2025 | Q3 2025 | -$0.21 | -$0.34 | -0.13 | $283.90 K | $260.00 K |
| 08/11/2025 | Q2 2025 | N/A | -$0.30 | N/A | $292.50 K | $518.00 K |
| 05/12/2025 | Q1 2025 | -$0.24 | -$0.26 | -0.02 | $127.50 K | $2.14 M |
| 03/24/2025 | Q4 2024 | -$0.40 | -$1.93 | -1.53 | $101.67 K | $1.49 M |
| 11/12/2024 | Q3 2024 | -$0.44 | -$0.98 | -0.54 | $178.33 K | $115.00 K |
| 08/08/2024 | Q2 2024 | N/A | -$0.36 | N/A | $318.55 K | $104.00 K |
| 05/15/2024 | Q1 2024 | -$0.67 | -$1.13 | -0.46 | $350.00 K | $176.00 K |
| 04/15/2024 | Q4 2023 | N/A | -$1.96 | N/A | $225.00 K | $314.00 K |
| 11/09/2023 | Q3 2023 | -$1.01 | -$0.81 | 0.2 | $312.50 K | $429.00 K |
| 08/10/2023 | Q2 2023 | N/A | -$1.07 | N/A | $362.50 K | $463.00 K |
| 05/15/2023 | Q1 2023 | N/A | $0.40 | N/A | $346.40 K | $297.00 K |
| 04/12/2023 | Q4 2022 | N/A | -$7.64 | N/A | $1.48 M | $274.00 K |
| 11/10/2022 | Q3 2022 | -$2.27 | -$1.59 | 0.68 | $2.71 M | $67.00 K |
| 08/11/2022 | Q2 2022 | N/A | -$1.40 | N/A | $2.24 M | $237.00 K |
| 05/12/2022 | Q1 2022 | N/A | -$2.32 | N/A | $3.52 M | $380.00 K |
| 05/02/2022 | Q4 2021 | N/A | -$7.88 | N/A | $1.75 M | $3.59 M |
In the previous quarter, Insight Molecular Diagnostics Inc. (:IMDX) reported $-0.1 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.236 by $0.136.
The conference call for Insight Molecular Diagnostics Inc.'s latest earnings report can be listened to online.
The conference call transcript for Insight Molecular Diagnostics Inc.'s latest earnings report can be read online.
Insight Molecular Diagnostics Inc. (:IMDX) has a recorded annual revenue of $4.06 M.
Insight Molecular Diagnostics Inc. (:IMDX) has a recorded net income of $-50,222,000.Insight Molecular Diagnostics Inc. has generated $-1.65 earnings per share over the last four quarters.
Insight Molecular Diagnostics Inc. (:IMDX) has a price-to-earnings ratio of -1.54 and price/earnings-to-growth ratio is -0.02.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED